Obsidian Therapeutics, Inc. announced that it has received $160.5 million in funding from a group of investors

▤ Summary

Obsidian Therapeutics, Inc. announced that it has received $160.5 million in a round of funding led by new investor Wellington Management Company LLP on April 3, 2024. The transaction included participation from new investors Foresite Capital Management, LLC, Novo Holdings A/S, Paradigm Biocapital Advisors LP, RTW Investments, LP, Woodline Partners LP, funds and accounts advised by T. Rowe Price Group, Inc., returning investors Atlas Venture L.P., Blue Owl Healthcare Opportunities, Bristol-Myers Squibb Company, Deep Track Capital, LP, Logos Capital LLC, RA Capital Management, L.P., TCG Crossover Management, LLC, Samsara BioCapital LLC, Surveyor Capital Management. Ray Camahort will join board of directors of the company.

▦ Linked Companies